Skip to content

THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.: 10-Q filed 2019-11-20

What THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. reported in its quarterly report filed 2019-11-20 (fiscal Q3 2019): 31 published measures, 86 facts as tagged in accession 0001078782-19-000873.

This filing

Form
10-Q (quarterly report)
Filed
2019-11-20
Fiscal period
fiscal Q3 2019
Accession
0001078782-19-000873 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2019-09-30327,884USD
At 2018-12-31206,931USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2019-09-30-1,632,364USD
At 2018-12-31-1,810,468USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2019-09-3020,015USD
At 2018-12-3122,397USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2019-07-01 to 2019-09-30-446,236USD92
2019-01-01 to 2019-09-30-1,049,402USD273
2018-07-01 to 2018-09-30-167,773USD92
2018-01-01 to 2018-09-30-1,058,465USD273
2017-07-01 to 2017-09-30-167,774USD92

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2019-01-01 to 2019-09-30-257,923USD273
2018-01-01 to 2018-09-30-380,825USD273

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2019-07-01 to 2019-09-3011,278USD92
2019-01-01 to 2019-09-3022,673USD273
2018-01-01 to 2018-09-304,920USD273
2017-07-01 to 2017-09-303,301USD92

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2019-01-01 to 2019-09-30255,541USD273
2018-01-01 to 2018-09-30402,016USD273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2019-09-30-8,184,980USD
At 2018-12-31-7,135,578USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2019-01-01 to 2019-09-3074,000USD273
2018-01-01 to 2018-09-30283,750USD273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2019-07-01 to 2019-09-30-199,627USD92
2019-01-01 to 2019-09-30-826,449USD273
2018-01-01 to 2018-09-30-689,712USD273
2017-07-01 to 2017-09-30-256,595USD92

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2019-09-30145,189USD
At 2018-12-31135,918USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2019-07-01 to 2019-09-3097,598USD92
2019-01-01 to 2019-09-30287,773USD273
2018-01-01 to 2018-09-30160,429USD273
2017-07-01 to 2017-09-3071,406USD92

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2019-09-301,960,248USD
At 2018-12-312,017,399USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2019-09-30324,740USD
At 2018-12-31320,812USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2019-09-302,544USD
At 2018-12-310USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2019-07-01 to 2019-09-30209,627USD92
2019-01-01 to 2019-09-30846,663USD273
2018-01-01 to 2018-09-30693,863USD273
2017-07-01 to 2017-09-30259,336USD92

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2019-09-301,050USD

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2019-07-01 to 2019-09-3010,000USD92
2019-01-01 to 2019-09-3020,214USD273
2018-01-01 to 2018-09-304,151USD273
2017-07-01 to 2017-09-302,741USD92

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2019-07-01 to 2019-09-3024,812USD92
2019-01-01 to 2019-09-3031,044USD273
2018-01-01 to 2018-09-3073,760USD273
2017-07-01 to 2017-09-3033,896USD92

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2019-09-301,439,037,647shares
At 2018-12-311,011,063,182shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2019-09-3030,188USD
At 2018-12-3132,570USD
At 2018-09-3031,376USD
At 2017-12-3110,185USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2019-09-305,113,579USD
At 2018-12-314,314,047USD

Total equity including noncontrolling interests

Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.

PeriodValueUnitDays
At 2019-09-30-1,632,364USD
At 2019-06-30-1,483,996USD
At 2018-12-31-1,810,468USD
At 2018-09-30-1,472,678USD
At 2018-06-30-1,748,755USD
At 2017-12-31-1,314,354USD

Long-term debt

Long-term borrowings under this concept, which can include the current portion depending on presentation. It is not total liabilities and may exclude leases and other obligations.

PeriodValueUnitDays
At 2019-09-30493,868USD
At 2018-09-30458,487USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2019-09-30962,441USD
At 2018-12-31717,723USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2019-07-01 to 2019-09-3018,269USD92
2019-01-01 to 2019-09-3051,890USD273
2018-01-01 to 2018-09-3058,724USD273
2017-07-01 to 2017-09-3021,308USD92

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2019-07-01 to 2019-09-30-246,609USD92
2019-01-01 to 2019-09-30-222,953USD273
2018-01-01 to 2018-09-30-368,753USD273
2017-07-01 to 2017-09-3088,821USD92

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2019-01-01 to 2019-09-3076,430USD273
2018-01-01 to 2018-09-30249,000USD273

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2019-01-01 to 2019-09-302,544USD273
2018-01-01 to 2018-09-302,020USD273

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2019-01-01 to 2019-09-301,050USD273
2018-01-01 to 2018-09-3030USD273

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2019-01-01 to 2019-09-303,147USD273
2018-01-01 to 2018-09-30-8,444USD273

Inspect the source

Entity
THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. / CIK 0001419051
Captured
2026-09-21T17:19:45.690Z
SEC response SHA-256
ad44380627053f8e0101ecf19c259e20a0a85d4c20ee53d5400d9dcf00541fc2

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001419051.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))